IBD Evidence

Triniaeth

Biologics a thechnegau uwch eu cymharu

Am y tro cyntaf, mae'r cwestiwn cymharol — pa feddyginiaeth, nid a yw meddyginiaeth — yn cael atebion meta-dadansoddol.

Diweddarwyd 2 min darllen 40 dyfyniadau Cryfder tystiolaeth 5/5

Cynffon endosgopig wedi'i ddefnyddio ar gyfer polypectomi gastroberfeddol a cholonig
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Beth sydd wedi newid

Am ddwy ddegawd, roedd y sylfaen tystiolaeth yn feddyginiaeth yn erbyn plasebo, a ddywedodd wrth clinigwyr fod biologics yn gweithio ac ni chafodd unrhyw beth am ba un i'w ddewis. Mae dadansoddiad meta-rhwydwaith wedi newid hynny trwy ddefnyddio cymarwyr rhannol i raddio therapiadau yn anuniongyrchol [1][4].

Mae'r canlyniad ymarferol yn golygu y gellir nawr rhesymu am ddewis cyntaf yn hytrach na'i ddirwyn i ben, ac mae gwahaniaethau rhwng asiantau ar ddynodi yn erbyn cynnal, a pharhad yn erbyn diogelwch, yn weladwy.

Effeithiolrwydd cymharol therapiadau uwch

Y dosbarthiadau

Dosbarthiadau therapiadau uwch yn IBD
DosbarthMechanwaithNodau
Anti-TNFBlociau ffactor necrosis tiwmor alphaY cofrestr hiraf; mae immunogenicity yn gyfyngiad pennaf
Anti-integredinBlociau symudiad leucocyte i'r coluddynDewisol i'r coluddyn, felly diogelwch systemig ffafriol
Anti-IL-12/23 a anti-IL-23Blociau signalu interleukinProffil effeithiolrwydd a diogelwch cryf mewn cymariaethau diweddar
Inawt JAKMoleciwl bach, signalu mewnolOral a chyflym; rhybuddion cardiofasgwlaidd a thrombois
Modulatorau S1PCynhelir lymphocytes yn y nodau limffOral; yn newydd, llai o ddata tymor hir

Trin i darged, nid i symptomau

Mae'r newid mwyaf pwysig yn rheoli IBD yw bod symptomau yn ddirprwy wael ar gyfer llid. Mae pobl yn teimlo'n dda gyda llid actif ac yn teimlo'n wael mewn adferiad. Mae'r cyfarwyddyd Ewropeaidd presennol felly yn targedu marcwyr gwrthrychol — calprotectin fecal, iachâd endosgopig — yn hytrach na sut mae'r claf yn adrodd ei deimlad.

Mae hyn hefyd yn ateb y cwestiwn dietegol a godwyd ar y dudalen ddeiet: ymyriad sy'n gwella symptomau heb wella marcwyr gwrthrychol ddim wedi trin y clefyd.

Pan nad yw un feddyginiaeth yn ddigon

Mae triniaeth biologig ddwbl neu therapi moleciwl bach cyfuniad wedi'i gwerthuso ar gyfer clefyd gwrthod [3]. Mae'n parhau i fod yn benderfyniad arbenigol gyda sylfaen dystiolaeth gyfyngedig, ac yma y mae gwaith un gell sy'n nodi amrywiad ymateb [2] yn debygol o newid ymarfer — trwy ragweld pa fecanwaith i dargedu mewn claf penodol yn hytrach na'i ddarganfod trwy fethiant dilynol.

Golygfa o'r stryd o adeilad fferyllfa'r gorsaf yn Bautzen, yr Almaen
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Cwestiynau cyffredin

Pa biologig sy'n gorau?
Mae dadansoddiadau meta-rhwydwaith bellach yn eu raddio [1][4], a dibynna'r dewis cywir ar leoliad clefyd, difrifoldeb, nodweddion allanol a'ch goddefgarwch risg eich hun.
A allaf stopio unwaith y byddaf yn adfer?
Mae tynnu yn dod â risg sylweddol o ailgodi. Mae'n benderfyniad i'w wneud gyda'ch tîm, yn seiliedig ar farcwyr gwrthrychol yn hytrach na sut rydych chi'n teimlo.
A yw biologics yn beryglus?
Maent yn cario risgiau gwirioneddol, yn bennaf heintiad. Mae llid heb ei thrin hefyd yn cario risg, a'r cymhariaeth yw rhwng dau risg yn hytrach na yn erbyn dim.
Beth yw calprotectin?
Marcwr stool o lid coluddyn. Dyma sut y mae "trinio i darged" yn cael ei fonitro mewn gwirionedd.
Y dystiolaeth y tu ôl i'r dudalen hon Bar wedi'i stackio sy'n dangos cyfansoddiad y 20 cyhoeddiad a grybwyllir ar y dudalen hon yn ôl math astudiaeth. 24meta-analysis (24)
20 cyhoeddiadau, 2015–2025. Mae hwn yn sylfaen bennaf arsylwi. Gall sefydlu bod pethau'n digwydd gyda'i gilydd; ni all benderfynu pa un sy'n achosi'r llall. Ffynhonnell: rhestr dyfynnu'r dudalen hon ei hun, isod.

Cyfeiriadau

Mae pob dyfyniad isod yn cysylltu â'r cofrestr adolygedig cyfoes gwreiddiol ar PubMed neu trwy DOI. Nid yw dim yma yn gymhwysedd ar gyfer cyngor meddygol.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  3. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  4. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  5. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  6. S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations Nast A, Altenburg A, Augustin M, et al. · Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026 · Clinical guideline DOIPubMed 41641952Full text
  7. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  8. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  9. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of Telemedicine in Inflammatory Bowel Disease Aguas Peris M, Del Hoyo Francisco J, Nos Mateu P, et al. · Gastroenterologia y hepatologia · 2025 · Clinical guideline DOIPubMed 39672505
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease Scott FI, Ananthakrishnan AN, Click B, et al. · Gastroenterology · 2025 · Clinical guideline DOIPubMed 41274746Full text
  12. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 Moran GW, Gordon M, Sinopolou V, et al. · Gut · 2025 · Clinical guideline DOIPubMed 40550582
  13. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  14. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  15. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  16. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  17. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  18. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  19. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  20. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  21. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  22. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  23. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  24. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  25. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  26. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  27. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  28. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  29. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients Sicilia B, Vicente R, Arias L, et al. · Gastroenterologia y hepatologia · 2021 · Clinical guideline DOIPubMed 33592179
  30. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  31. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting De Simone B, Davies J, Chouillard E, et al. · World journal of emergency surgery : WJES · 2021 · Clinical guideline DOIPubMed 33971899Full text
  32. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  33. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  34. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  35. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  36. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  37. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  38. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  39. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  40. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419

Cafodd y dudalen hon ei thrawsgrifiad yn awtomatig o Saesneg. Mae'r dyfyniadau a'r rhifau heb newid. Darllenwch y gwreiddiol Saesneg os yw unrhyw beth yn darllen yn rhy ddieithr. Darllenwch y gwreiddiol Saesneg